SMT201300106B - Composizioni biodisponibili di composto alfa-(N-sulfonammido)acetammide amorfo - Google Patents
Composizioni biodisponibili di composto alfa-(N-sulfonammido)acetammide amorfoInfo
- Publication number
- SMT201300106B SMT201300106B SM201300106T SM201300106T SMT201300106B SM T201300106 B SMT201300106 B SM T201300106B SM 201300106 T SM201300106 T SM 201300106T SM 201300106 T SM201300106 T SM 201300106T SM T201300106 B SMT201300106 B SM T201300106B
- Authority
- SM
- San Marino
- Prior art keywords
- amorphous
- sulfonamido
- alpha
- acetamide compound
- bioavailable compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- -1 acetamide compound Chemical class 0.000 title 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 title 1
- XEAOPVUAMONVLA-QGZVFWFLSA-N Avagacestat Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](CCC(F)(F)F)C(=O)N)CC(C(=C1)F)=CC=C1C=1N=CON=1 XEAOPVUAMONVLA-QGZVFWFLSA-N 0.000 abstract 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 abstract 1
- 239000007962 solid dispersion Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16906609P | 2009-04-14 | 2009-04-14 | |
| PCT/US2010/030679 WO2010120662A2 (en) | 2009-04-14 | 2010-04-12 | Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201300106B true SMT201300106B (it) | 2013-11-08 |
Family
ID=42664672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201300106T SMT201300106B (it) | 2009-04-14 | 2013-09-24 | Composizioni biodisponibili di composto alfa-(N-sulfonammido)acetammide amorfo |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20100261768A1 (enExample) |
| EP (1) | EP2419086B1 (enExample) |
| JP (1) | JP2012524090A (enExample) |
| KR (1) | KR20120027142A (enExample) |
| CN (1) | CN102387788B (enExample) |
| AR (1) | AR076306A1 (enExample) |
| AU (1) | AU2010236701A1 (enExample) |
| BR (1) | BRPI1012523A2 (enExample) |
| CA (1) | CA2758709A1 (enExample) |
| DK (1) | DK2419086T3 (enExample) |
| EA (1) | EA201171207A1 (enExample) |
| ES (1) | ES2426403T3 (enExample) |
| HR (1) | HRP20130807T1 (enExample) |
| MX (1) | MX2011010513A (enExample) |
| NZ (1) | NZ595411A (enExample) |
| PL (1) | PL2419086T3 (enExample) |
| PT (1) | PT2419086E (enExample) |
| SI (1) | SI2419086T1 (enExample) |
| SM (1) | SMT201300106B (enExample) |
| TW (1) | TW201043269A (enExample) |
| WO (1) | WO2010120662A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1289469C (zh) | 2001-12-20 | 2006-12-13 | 布里斯托尔-迈尔斯斯奎布公司 | α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂 |
| US8044077B2 (en) | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| US7977362B2 (en) | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| AR087277A1 (es) * | 2011-07-21 | 2014-03-12 | Bristol Myers Squibb Co | Composiciones biodisponibles de compuestos amorfos de piperidinilo, composicion farmaceutica, metodos |
| US20150045353A1 (en) * | 2013-08-09 | 2015-02-12 | Neurogenetic Pharmaceuticals, Inc. | Formulations containing gamma secretase modulators, methods for preparation and delivery thereof |
| TWI765410B (zh) | 2014-08-08 | 2022-05-21 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體的用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3999007A (en) * | 1975-10-09 | 1976-12-21 | Carl Joseph Crane | Aircraft visual approach/landing reproducer device and system |
| US5136301A (en) * | 1989-08-30 | 1992-08-04 | Rockwell International Corporation | Primary flight display system having a vertical linear altimeter |
| US5274094A (en) * | 1990-08-15 | 1993-12-28 | British Bio-Technology Limited | Production of heterobicyclic containing benzene sulfonamides |
| GB9202791D0 (en) * | 1992-02-11 | 1992-03-25 | British Bio Technology | Compounds |
| DE69606804T2 (de) * | 1995-06-20 | 2000-06-15 | Honeywell, Inc. | Integriertes System zur Grundkollisionsvermeidung |
| US5977141A (en) * | 1995-11-17 | 1999-11-02 | Warner-Lambert Company | Sulfonamide inhibitors of matrix metalloproteinases |
| US6233522B1 (en) * | 1998-07-06 | 2001-05-15 | Alliedsignal Inc. | Aircraft position validation using radar and digital terrain elevation database |
| US6313123B1 (en) * | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
| US6570531B1 (en) * | 2000-04-27 | 2003-05-27 | Rockwell Collins, Inc. | Satellite navigation receiver designed for compatibility with aircraft automatic landing systems |
| US6483454B1 (en) * | 2000-11-28 | 2002-11-19 | Bae Systems Aerospace Inc. | Close formation aircraft collision avoidance |
| CN1289469C (zh) * | 2001-12-20 | 2006-12-13 | 布里斯托尔-迈尔斯斯奎布公司 | α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂 |
| CN101274926A (zh) * | 2003-03-31 | 2008-10-01 | 惠氏公司 | β淀粉样蛋白生成抑制剂含氟和三氟烷基杂环磺酰胺及其衍生物 |
| US20050048112A1 (en) * | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
| FR2870605B1 (fr) * | 2004-05-18 | 2010-10-08 | Airbus France | Procede et dispositif de guidage automatique d'un aeronef, pour un vol au moins en partie a basse altitude |
| FR2880456B1 (fr) * | 2005-01-03 | 2007-02-23 | Airbus France Sas | Procede et dispositif d'alerte sonore lors de la desactivation d'un pilote automatique d'un aeronef |
| FR2886439B1 (fr) * | 2005-05-24 | 2010-11-05 | Eurocopter France | Procede et dispositif d'aide au pilotage d'un aeronef a basse altitude |
| CN101384250A (zh) * | 2005-11-09 | 2009-03-11 | 诺瓦提斯公司 | 利用临时增塑剂制备药物组合物的方法 |
| FR2897448B1 (fr) * | 2006-02-14 | 2008-03-14 | Airbus France Sas | Procede et systeme d'aide au pilotage d'un aeronef. |
| JP2009528281A (ja) * | 2006-02-17 | 2009-08-06 | ワイス | スルホンアミド置換アルコールおよびその中間体の調製方法 |
| TW200732295A (en) * | 2006-02-17 | 2007-09-01 | Wyeth Corp | Selective N-sulfonylation of 2-amino trifluoroalkyl substituted alcohols |
| WO2007109604A2 (en) * | 2006-03-20 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| US20070218012A1 (en) * | 2006-03-20 | 2007-09-20 | Bittorf Kevin J | Pharmaceutical Compositions |
| FR2911988B1 (fr) * | 2007-01-26 | 2016-03-25 | Airbus France | Procede et dispositif pour determiner une hauteur maximale de stabilisation lors de la phase finale de vol d'un avion |
| US8084477B2 (en) * | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
-
2010
- 2010-04-08 TW TW099110918A patent/TW201043269A/zh unknown
- 2010-04-09 US US12/757,304 patent/US20100261768A1/en not_active Abandoned
- 2010-04-12 CA CA2758709A patent/CA2758709A1/en not_active Abandoned
- 2010-04-12 BR BRPI1012523A patent/BRPI1012523A2/pt not_active Application Discontinuation
- 2010-04-12 SI SI201030355T patent/SI2419086T1/sl unknown
- 2010-04-12 JP JP2012506089A patent/JP2012524090A/ja active Pending
- 2010-04-12 NZ NZ595411A patent/NZ595411A/xx not_active IP Right Cessation
- 2010-04-12 MX MX2011010513A patent/MX2011010513A/es unknown
- 2010-04-12 WO PCT/US2010/030679 patent/WO2010120662A2/en not_active Ceased
- 2010-04-12 ES ES10714413T patent/ES2426403T3/es active Active
- 2010-04-12 CN CN2010800160778A patent/CN102387788B/zh not_active Expired - Fee Related
- 2010-04-12 EA EA201171207A patent/EA201171207A1/ru unknown
- 2010-04-12 KR KR1020117024035A patent/KR20120027142A/ko not_active Withdrawn
- 2010-04-12 HR HRP20130807AT patent/HRP20130807T1/hr unknown
- 2010-04-12 PT PT107144131T patent/PT2419086E/pt unknown
- 2010-04-12 EP EP10714413.1A patent/EP2419086B1/en not_active Not-in-force
- 2010-04-12 DK DK10714413.1T patent/DK2419086T3/da active
- 2010-04-12 AU AU2010236701A patent/AU2010236701A1/en not_active Abandoned
- 2010-04-12 PL PL10714413T patent/PL2419086T3/pl unknown
- 2010-04-14 AR ARP100101258A patent/AR076306A1/es unknown
-
2013
- 2013-09-24 SM SM201300106T patent/SMT201300106B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011010513A (es) | 2011-11-29 |
| PL2419086T3 (pl) | 2013-11-29 |
| ES2426403T3 (es) | 2013-10-23 |
| WO2010120662A3 (en) | 2011-09-15 |
| EP2419086B1 (en) | 2013-06-26 |
| DK2419086T3 (da) | 2013-09-30 |
| CN102387788B (zh) | 2013-07-10 |
| PT2419086E (pt) | 2013-09-04 |
| TW201043269A (en) | 2010-12-16 |
| AU2010236701A1 (en) | 2011-10-20 |
| US20100261768A1 (en) | 2010-10-14 |
| SI2419086T1 (sl) | 2013-10-30 |
| BRPI1012523A2 (pt) | 2016-03-29 |
| EP2419086A2 (en) | 2012-02-22 |
| KR20120027142A (ko) | 2012-03-21 |
| CN102387788A (zh) | 2012-03-21 |
| AR076306A1 (es) | 2011-06-01 |
| NZ595411A (en) | 2013-02-22 |
| HRP20130807T1 (hr) | 2013-09-30 |
| CA2758709A1 (en) | 2010-10-21 |
| EA201171207A1 (ru) | 2012-03-30 |
| JP2012524090A (ja) | 2012-10-11 |
| WO2010120662A2 (en) | 2010-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201300106B (it) | Composizioni biodisponibili di composto alfa-(N-sulfonammido)acetammide amorfo | |
| MX2007014892A (es) | Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico . | |
| SI2576523T1 (sl) | Kristalinične oblike 4-(5-(3-kloro-5-(trifluorometil)fenil)-4,5-dihidro 5-(trifluorometil)-3-izoksazolil)-N-(2-okso-2-((2,2,2-trifluoroetil) amino)etil)-1 naftalenkarboksamida | |
| DK1874306T3 (da) | Sammensætninger af en oralt aktiv 1,2,4-oxadiazol til nonsens-mutationssuppressionsterapi | |
| NL1029799A1 (nl) | Enantiomeer zuivere aminoheteroarylverbindingen als proteïnekinaseremmers. | |
| WO2006100635A3 (en) | Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists | |
| NO20091553L (no) | Fenylderivater og deres anvendelse som immunmodulatorer | |
| NO20083630L (no) | Nye pyridinderivater | |
| NO20071593L (no) | Pyrimidinderivater | |
| NO20090628L (no) | Pyridizinon derivativater | |
| MX2011010514A (es) | Composiciones de capsulas biodisponibles de compuesto amorfo alfa-(n-sulfonamido)acetamida. | |
| EA200802170A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
| DK2147098T3 (da) | Anvendelse af proteinhydrolysater til stabilisering af metalloprotease-detergent-formuleringer | |
| NO20076648L (no) | Novel thiophene derivatives | |
| DK1784396T3 (da) | Pyrazol-substituerede aminoheteroaryl-forbindelser som proteinkinase-inhibitorer | |
| DK2073805T3 (da) | Fremgangsmåder til dosering af en oralt aktiv 1,2,4-oxadiazol til terapi for suppression af nonsens-mutation | |
| NO20091395L (no) | Nye tiofenderivater | |
| WO2010055119A3 (en) | Pharmaceutical composition comprising pimobendan | |
| IL184558A0 (en) | Sustained release composition of protein drug | |
| DK1957656T3 (da) | Fermentativ fremstilling af lysin | |
| DK1954241T3 (da) | Zonisamid-formulering med vedvarende frigivelse | |
| MX2010003989A (es) | Composicion zibotentan que contiene mannitol y/o celulosa microcristalina. | |
| IL219013A0 (en) | Novel solid form of 4-[[(6-chloropyridin-3-yl)methyl(2,2-difluoroethy)amino]furan-2(5h)-one | |
| WO2006002077A3 (en) | Stable pharmaceutical formulations of benzimidazole compounds | |
| DK1809253T3 (da) | Stabiliseret frysetørret formulering til cephalosporinderivater |